HLS Therapeutics (TSX:HLS) Other Financing: C$-1.92 Mil (TTM As of Mar. 2026)


TSX:HLS HLS Therapeutics Inc TSX:HLS
62 GF Score
Price C$4.26
GF Value C$4.47
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is HLS Therapeutics Other Financing?

HLS Therapeutics TSX:HLS +2.90% 62 Other Financing is C$-1.92 Mil as of Mar. 2026. GuruFocus rates TSX:HLS with a GF Score™ of 62/100 and a GF Value™ of C$4.47 (Fairly Valued). The stock has 4 warning signs investors should review.

HLS Therapeutics's Other Financing for the three months ended in Mar. 2026 was C$0.00 Mil.

HLS Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was C$-1.92 Mil.

HLS Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for HLS Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HLS Therapeutics Other Financing Chart

HLS Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.28 -0.62 -1.65 -1.70 -1.92

HLS Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -1.69 -0.23 0.00
TSX:HLS
62GF Score
HLS Therapeutics Inc TSX:HLS
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HLS Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of C$-1.92 Mil mean?
HLS Therapeutics (TSX:HLS) has a Other Financing of C$-1.92 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for HLS Therapeutics and its competitors.
Is HLS Therapeutics' Other Financing too high?
HLS Therapeutics' current Other Financing is C$-1.92 Mil. Overall, HLS Therapeutics has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Other Financing compare to ZTS and UTHR?
HLS Therapeutics' Other Financing of C$-1.92 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for HLS Therapeutics and its competitors. HLS Therapeutics's current Other Financing is C$-1.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.47, compared to a current price of C$4.26 — trading 4.7% below its estimated fair value. The current Other Financing is C$-1.92 Mil. HLS Therapeutics' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Other Financing is C$-1.92 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of C$4.26 is trading 4.7% below its estimated GF Value™ of C$4.47. GuruFocus considers HLS Therapeutics to be Fairly Valued.

Key valuation signals for TSX:HLS:

  • Other Financing: C$-1.92 Mil
  • GF Value™: C$4.47 vs. price of C$4.26 (4.7% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HLS Therapeutics Business Description

Other Exchanges HLTRF:USA74D:Germany
Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
62GF Score

Get the complete analysis for TSX:HLS

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$4.26
Price
C$4.47
GF Value